| Description | Surzebiclimab (BGB-A425), a humanized variant IgG1 monoclonal antibody, targets and binds with high affinity (K D = 0.36 nM) and specificity to the extracellular domain of T-cell immunoglobulin and mucin-domain containing-3 (TIM-3). This compound is utilized in cancer research [1]. |
| In vitro | Surzebiclimab (BGB-A425; 0.1-100 μg/mL) 有效地抑制了Tim-3与PtdSer之间的相互作用，并提升了原代T细胞产生IFN-γ的能力以及NK细胞介导的肿瘤细胞细胞毒性[1]。此外，Surzebiclimab单用或与抗PD-1抗体BGB-A317联用时，能够增强T细胞对异质抗原的反应，并促进了Tim-3受体在细胞表面的内化作用[1]。 |
| In vivo | Surzebiclimb（BGB-A425）与BGB-A317联合应用，在小鼠异种移植瘤模型中有效抑制了肿瘤生长[1]。 |
| Synonyms | BGB-A425 |
| molecular weight | N/A |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 years | Shipping with blue ice. |